Improved long-term survival with combined modality therapy for pediatric nasopharynx cancer

Citation
Sl. Wolden et al., Improved long-term survival with combined modality therapy for pediatric nasopharynx cancer, INT J RAD O, 46(4), 2000, pp. 859-864
Citations number
29
Categorie Soggetti
Radiology ,Nuclear Medicine & Imaging","Onconogenesis & Cancer Research
Journal title
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
ISSN journal
03603016 → ACNP
Volume
46
Issue
4
Year of publication
2000
Pages
859 - 864
Database
ISI
SICI code
0360-3016(20000301)46:4<859:ILSWCM>2.0.ZU;2-E
Abstract
Purpose: Nasopharynx cancer is a rare malignancy in childhood. This study a ims to determine the role of chemotherapy, the optimal dose of radiation, a nd the long-term outcome for children with locoregional disease. Methods and Materials: Thirty-three patients [median age 14 (range: 12-20) years] were treated for Stage I-IVB nasopharynx cancer. Thirteen patients ( 39%) received radiotherapy alone and 20 patients (61%) had chemotherapy and radiotherapy. The median radiation dose to the primary tumor was 66 Gy (ra nge: 54-72 Gy). The median follow-up time for surviving patients was 8.4 ye ars (range: 0.5-23.6 years). Results: The actuarial 10-year locoregional relapse-free survival, distant metastases-free survival, and overall survival rates were 77%, 68%, and 58% , respectively. Locoregional control was improved for patients treated with radiation doses >60 Gy compared to those receiving less than or equal to 6 0 Gy (93% vs. 60%, p < 0.03). The addition of chemotherapy had no significa nt effect on locoregional control but did reduce the development of distant metastases (16% vs. 57%, p = 0.01). Combined modality therapy improved 10- year disease-free survival (84% vs. 35%, p < 0.01) and survival (78% vs. 33 %, p < 0.05) over radiation alone. The 10-year actuarial rate of severe com plications was 24%. Conclusions: Excellent locoregional control is achieved with radiotherapy t o the nasopharynx and neck when doses >60 Gy are used for gross disease. Th e addition of chemotherapy decreases the risk of distant metastases and inc reases survival. (C) 2000 Elsevier Science Inc.